PAR 4.08% 25.5¢ paradigm biopharmaceuticals limited..

Capital Raise, page-21

  1. 1,603 Posts.
    lightbulb Created with Sketch. 167
    I am going to be fascinated with how PAR
    management will come up with the finance to
    get these Phase 3 trials (002-003) completed
    and results presented to FDA, without resorting
    to the traditional CR.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.